Percutaneous closure of secundum atrial septal defect with a new self centring device ("angel wings")

Rickers, Carsten; Hamm, Christian W.; Stern, H.; Hofmann, Thomas; Franzen, Olaf; Schräder, Rainer; Sievert, Horst; Schranz, Dietmar; Michel‐Behnke, Ina; Vogt, Johannes; Kececioglu, D.; Sebening, W.; Eicken, Andreas; Meyer, H; Matthies, W.; Kleber, Franz X.; Hug, Jürgen; Weil, Jochen

doi:10.1136/hrt.80.5.517

Cited by 88 publications

(57 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[5][6][7][8][9][10][11][12][13][14][15] However, which is the best device for closure of ASD remains controversial. [5][6][7][8][9][10][11][12][13][14][15][16][17] For central-located secundum ASD of small to medium size, closure with a device is strongly recommended. Sideris' button device had been reported to successfully close secundum ASD in some patients.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5] Transcatheter closure with different devices, such as Rashkind umbrella, Sideris' occluder, angel wings device, ASDOS occluder, and Clamshell device have been tried on human beings within the last 20 years. [6][7][8][9][10][11][12][13][14][15] The initial results were reported as acceptable, but opinions on the best device for transcatheter closure of ASD vary widely. [6][7][8][9][10][11][12][13][14][15][16][17] A total of 12 children were enrolled in the present study to evaluate the immediate and intermediate results of transcatheter closure of ASD by a Cardio-SEAL device.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Transcatheter Closure of Atrial Septal Defect with a CardioSEAL Device

Hwang

Lee

et al. 2000

Jpn Heart J

View full text Add to dashboard Cite

SUMMARYTranscatheter closure of an interatrial septal defect (ASD) with a CardioSEAL device was successfully performed on 12 Taiwanese children. There were five boys and seven girls, aged from 3.6-13.9 (8.3 ± 3.2) years and with body weight of 15-57 (33.7 ± 14.7) kgs. After one year of follow-up studies, which included physical examination, ECG, chest X-ray and echocardiography, complete closure of ASD was achieved in nine (75%) patients. Two children with a trivial residual shunt were asymptomatic and without audible cardiac murmur. A girl had a small residual left to right atrial shunt by color Doppler echocardiography, but without audible cardiac murmur. There were no immediate or intermediate complications. Transcatheter implantation of the CardioSEAL device is a safe and proper treatment for children with non-complicated small to medium secundum ASD. (Jpn Heart J 2000; 41: 471-480)

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Transcatheter Closure of Atrial Septal Defect with a CardioSEAL Device

Hwang

Lee

et al. 2000

Jpn Heart J

View full text Add to dashboard Cite

show abstract

“…This device had two polyester fabric-covered square frames and a Nitinol frame with midpoint torsion spring eyelets. A circular hole with a diameter equal to one-half of the size of the disk was punched from the right disk with the margins sewn to the left-sided disk forming a www.intechopen.com conjoined ring, the centering mechanism (Rickers et al, 1998). Device sizes ranging from 12 to 40 mm were manufactured.…”

Section: Das Angel Wing Devicementioning

confidence: 99%

“…Clinical trials were undertaken in US and abroad (Rickers et al, 1998;Banerjee et al, 1999). Phase I clinical trial included 90 patients; 50 of these were ostium secundum ASDs (Banerjee et al, 1999;Das et al, 2003).…”

Section: Das Angel Wing Devicementioning

confidence: 99%

Historical Aspects of Transcatheter Occlusion of Atrial Septal Defects

Alapati¹,

Rao²

2012

Atrial Septal Defect

View full text Add to dashboard Cite

“…Thrombus developed on eight different types of transcatheter devices. All commercially available devices had at least one reported case of thrombosis: PFO-Star (17 patients) [4,5,8,15], ASDOS (13 patients) [5,7,[13][14][15], CardioSEAL Starflex (9 patients) [5,12,18,20], CardioSEAL (5 patients) [5,9,16,17,19], Angel Wings (4 patients) [5,17], Amplatzer (4 patients) [5,6,10,15], Buttoned (1 patient) [11], and Helex (1 patient) [5]. Patient age was available in half of the cases (mean age, 44.2 Ϯ 9.8 years).…”

Section: Thrombus Informationmentioning

confidence: 99%

Thrombosis after septal closure device placement: A review of the current literature

Sherman

Hagler

Cetta

2004

Cathet Cardio Intervent

View full text Add to dashboard Cite

Thrombus formation has been described for all types of commercially available transcatheter septal occlusion devices. Most reports have been single-institution case studies. Screening for hypercoagulable conditions prior to device placement and anticoagulation after device deployment has been variable. The objective of this study was to synthesize the current experience with device thrombosis; the Medline database from 1980 until 2004 was searched. Seventeen articles identified 54 unique patients with device thrombosis. Thrombus developed on eight different types of transcatheter devices. All commercially available devices had at least one reported case of thrombosis. Patient mean age was 44.2 +/- 9.8 years. Thrombosis was diagnosed at a mean of 5 months after device deployment. Prior to device placement, 12 patients had normal coagulation evaluations and 5 had coagulopathies. For 37 patients, no mention was made in the report of coagulation studies. Prior to device thrombosis, 26 patients received aspirin and clopidogrel, 15 patients received aspirin alone, 8 received warfarin, 2 heparin alone, 1 aspirin and warfarin. One patient with hemophilia A received no anticoagulation and in one case treatment prior to thrombosis was not reported. After device thrombosis, 35 patients were treated with warfarin with thrombus resolution, 2 had successful lytic therapy, 1 was treated with heparin alone. Sixteen patients had surgical explantation of the device. Septal occlusion device thrombosis is rare. All types of commercially available devices have been associated with thrombosis. All patients should have early (< or = 3 months) echocardiographic surveillance for device thrombosis. Thorough coagulation evaluation is imperative prior to transcatheter device placement.

show abstract

Percutaneous closure of secundum atrial septal defect with a new self centring device ("angel wings")

Cited by 88 publications

References 26 publications

Transcatheter Closure of Atrial Septal Defect with a CardioSEAL Device

Transcatheter Closure of Atrial Septal Defect with a CardioSEAL Device

Historical Aspects of Transcatheter Occlusion of Atrial Septal Defects

Thrombosis after septal closure device placement: A review of the current literature

Contact Info

Product

Resources

About